Effect of Osteoporosis Treatments on Osteoarthritis Progression in Postmenopausal Women: A Review of the Literature.

Autor: Ho WC; School of Medicine, Tzu Chi University, Hualien, Taiwan., Chang CC; School of Medicine, Tzu Chi University, Hualien, Taiwan., Wu WT; School of Medicine, Tzu Chi University, Hualien, Taiwan.; Department of Orthopedics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.; Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan., Lee RP; Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan., Yao TK; Department of Orthopedics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan., Peng CH; Department of Orthopedics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan., Yeh KT; School of Medicine, Tzu Chi University, Hualien, Taiwan. micrograft@tzuchi.com.tw.; Department of Orthopedics, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan. micrograft@tzuchi.com.tw.; Graduate Institute of Clinical Pharmacy, Tzu Chi University, Hualien, Taiwan. micrograft@tzuchi.com.tw.
Jazyk: angličtina
Zdroj: Current rheumatology reports [Curr Rheumatol Rep] 2024 May; Vol. 26 (5), pp. 188-195. Date of Electronic Publication: 2024 Feb 19.
DOI: 10.1007/s11926-024-01139-8
Abstrakt: Purpose of Review: The purpose of this literature review was to determine if medications used to treat osteoporosis are also effective for treating osteoarthritis (OA).
Recent Findings: A total of 40 relevant articles were identified. Studies were categorized into those (1) discussing estrogen and selective estrogen receptor modulators (SERMs), (2) bisphosphonates, (3) parathyroid hormone (PTH) analogs, and (4) denosumab, and (5) prior review articles. A large amount of evidence suggests that estrogen and SERMs are effective at reducing OA symptoms and disease progression. Evidence suggests that bisphosphonates, the most common medications used to treat osteoporosis, can reduce OA symptoms and disease progression. In vivo studies suggest that PTH analogs may improve the cartilage destruction associated with OA; however, few human trials have examined its use for OA. Denosumab is approved to treat osteoporosis, bone metastases, and certain types of breast cancer, but little study has been done with respect to its effect on OA. The current evidence indicates that medications used to treat osteoporosis are also effective for treating OA. Estrogen, SERMs, and bisphosphonates have the most potential as OA therapies. Less is known regarding the effectiveness of PTH analogs and denosumab in OA, and more research is needed.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: